| (210) | Number of the EPO application | 18743314 |
| (220) | Filing date of the EPO application | 2018.06.29 |
| (80) | EPO patent specification publication (B) | EPB nr. 20/2021, 2021.05.19 |
| (110) | EPO patent number | 3645518 |
| (11) | Number of the document | MD 3645518 T2 |
| (21) | Number of the application | e 2020 0486 |
| (71) | Name(s) of applicant(s), code of the country | AMGEN INC., US; |
| (72) | Name(s) of inventor(s), code of the country | CAILLE Sebastien, US;
QUASDORF Kyle, US;
ROOSEN Philipp, US;
SHI Xianqing, US;
COSBIE Andrew, US;
WANG Fang, US;
WU Zufan, US;
NEERGUNDA Archana, US;
QUAN Bin Peter, US;
GUAN Lianxiu, US; |
| (73) | Name(s) of owner(s), code of the country | AMGEN INC., US; |
| (54) | Title of the invention | Synthesis of omecamtiv mecarbil |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 295/205 (2006.01.01); C07D 213/75 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.05.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2021.11.30 |
| (30) | Priority | 201762527174 P, 2017.06.30, US; 201862664363 P, 2018.04.30, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2018/040176, 2018.06.29 |
| (87) | International publication | WO 2019/006231, 2019.01.03 |